The stock price of Cullinan Therapeutics Inc (NASDAQ: CGEM) has plunged by -1.92 when compared to previous closing price of 8.32, but the company has seen a -9.13% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-04 that Advances Cullinan’s leadership in T cell engager (TCE) development for autoimmune diseases with both a CD19 TCE and BCMA TCE in its pipeline
Is It Worth Investing in Cullinan Therapeutics Inc (NASDAQ: CGEM) Right Now?
CGEM has 36-month beta value of -0.04. Analysts have mixed views on the stock, with 8 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CGEM is 35.92M, and currently, short sellers hold a 17.21% ratio of that float. The average trading volume of CGEM on June 19, 2025 was 433.77K shares.
CGEM’s Market Performance
CGEM’s stock has seen a -9.13% decrease for the week, with a 5.84% rise in the past month and a -5.66% fall in the past quarter. The volatility ratio for the week is 2.82%, and the volatility levels for the past 30 days are at 3.32% for Cullinan Therapeutics Inc The simple moving average for the last 20 days is -4.40% for CGEM stock, with a simple moving average of -29.40% for the last 200 days.
Analysts’ Opinion of CGEM
Many brokerage firms have already submitted their reports for CGEM stocks, with Stifel repeating the rating for CGEM by listing it as a “Buy.” The predicted price for CGEM in the upcoming period, according to Stifel is $22 based on the research report published on June 11, 2025 of the current year 2025.
UBS, on the other hand, stated in their research note that they expect to see CGEM reach a price target of $30. The rating they have provided for CGEM stocks is “Buy” according to the report published on October 24th, 2024.
Stifel gave a rating of “Buy” to CGEM, setting the target price at $40 in the report published on May 01st of the previous year.
CGEM Trading at 0.33% from the 50-Day Moving Average
After a stumble in the market that brought CGEM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.16% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CGEM starting from Jones Jeffrey Alan, who sale 4,895 shares at the price of $8.53 back on Feb 25 ’25. After this action, Jones Jeffrey Alan now owns 174,164 shares of Cullinan Therapeutics Inc, valued at $41,754 using the latest closing price.
AHMED NADIM, the President and CEO of Cullinan Therapeutics Inc, sale 12,529 shares at $8.53 during a trade that took place back on Feb 25 ’25, which means that AHMED NADIM is holding 430,621 shares at $106,872 based on the most recent closing price.
Stock Fundamentals for CGEM
The total capital return value is set at -0.38. Equity return is now at value -36.57, with -34.74 for asset returns.
Based on Cullinan Therapeutics Inc (CGEM), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -81.64.
Currently, EBITDA for the company is -167.15 million with net debt to EBITDA at 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.62.
Conclusion
To put it simply, Cullinan Therapeutics Inc (CGEM) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
